Molecure (WAR:MOC) Total Operating Expense: zł22.72 Mil (TTM As of Sep. 2025)


WAR:MOC Molecure SA WAR:MOC
29 GF Score
Price zł6.04
! 3 Warning Signs
View Full Analysis

What is Molecure Total Operating Expense?

Molecure WAR:MOC +3.78% 29 Total Operating Expense is zł22.72 Mil as of Sep. 2025. GuruFocus rates WAR:MOC with a GF Score™ of 29/100. The stock has 3 warning signs investors should review.

Molecure's Total Operating Expense for the three months ended in Sep. 2025 was zł5.09 Mil. Molecure's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 was zł22.72 Mil.

Molecure Total Operating Expense Related Terms

Molecure Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Molecure's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecure Total Operating Expense Chart

Molecure Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.83 10.99 15.35 28.03 28.89

Molecure Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.72 9.51 4.86 3.27 5.09
WAR:MOC
29GF Score
Molecure SA WAR:MOC
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecure Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was zł22.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of zł22.72 Mil mean?
Molecure (WAR:MOC) has a Total Operating Expense of zł22.72 Mil as of Sep. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Molecure and its competitors.
Is Molecure's Total Operating Expense too high?
Molecure's current Total Operating Expense is zł22.72 Mil. Overall, Molecure has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Molecure's Total Operating Expense compare to VRTX and REGN?
Molecure's Total Operating Expense of zł22.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Molecure and its competitors. Molecure's current Total Operating Expense is zł22.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecure stock overvalued right now?
Molecure (WAR:MOC) has a current Total Operating Expense of zł22.72 Mil. The current Total Operating Expense is zł22.72 Mil. Molecure's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Molecure (WAR:MOC), the current Total Operating Expense is zł22.72 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Molecure Business Description

Other Exchanges 1B1:Germany
Address Zwirki i Wigury 101, Warsaw, POL, 02-089
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
29GF Score

Get the complete analysis for WAR:MOC

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł6.04
Price